Genetics and cardiomyopathy: Where are we now?

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 6, 2005, Pages 465-483

  Murphy, Ross T ^a   Starling, Randall T ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL PRACTICE; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FABRY DISEASE; FAMILIAL DISEASE; FRIEDREICH ATAXIA; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HEART RIGHT VENTRICLE DYSPLASIA; HEREDITY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INFORMED CONSENT; INSURANCE; LEGAL ASPECT; LINKAGE ANALYSIS; NOONAN SYNDROME; PREDICTION; RELIABILITY; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEQUENCE ANALYSIS; TREATMENT PLANNING; WOLFF PARKINSON WHITE SYNDROME;

EID: 21344441228     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.6.465     Document Type: Review

References (26)

1. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841-842.
2. Codd MB, Sugrue DD, Gersh BJ, et al. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989; 80:564-572.
3. Kass S, MacRae C, Graber HL, et al. A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-1q1. Nat Genet 1994; 7:546-551.
4. Kamisago M, Sharma S, DePalma S, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343:1688-1696.
5. Murphy RT, Mogensen J, Shaw AL, Kobu T, Elliott PM, McKenna WJ. Troponin I is a novel recessive disease gene in familial dilated cardiomyopathy. Lancet 2004; 363:371-372.
6. Mogensen J, Murphy RT, Bahl A, et al. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2004; 44:2033-2040.
7. McNamara DM, MacGowan GA, London B. Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease. Am J Pharmacogenomics 2002; 2:73-78.
8. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002, 87:169-176.
9. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775-785.
10. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in genes for cardiac troponin T and a-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995; 332:1058-1064.
11. Mogensen J, Klausen I, Pedersen A, et al. Alpha-cardiac actin is a novel disease gene in familial HCM. J Clin Invest 1999; 103:r39-r43.
12. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105:1407-1411.
13. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42:1687-1713.
14. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med 1994; 330:913-919.
15. Baig MK, Golman JH, Caforio AL, et al. Familial DCM: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol 1998; 31:195-201.
16. Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107:2793-2798.
17. Mahon NG, Madden BP, Carforio ALP, et al. Immunohistological evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 39:455-462.
18. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
19. Dalakas MC, Park KY, Semino-Mora C, et al. Desmin myopathy: a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000; 343:770-780.
20. Tsubata S, Bowles KR, Vatta M, et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000; 106:655-662.
21. Fatkin D, MacCrae CA, Sasaki T, et al. Missense mutations in the rod domain of the Lamin a/c gene as causes of dilated cardiomyopathy and conduction system disease. N Engl J Med 1999; 341:1715-1724.
22. Schmitt JP. Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003; 299:1410-1413.
23. Bienengraeber M, Olson TM, Selivanov VA, et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Natl Genet 2004; 36:382-387.
24. McKoy G, Protonataris N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy, palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000; 355:2119-2124.
25. Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2. Hum Mol Genetics 2001; 10:189-194.
26. Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 2003; 111:209-216.